Advanced Enzyme Technologies posted robust financial results for FY 2025-26, with consolidated revenue growing 17% year-on-year to ₹745.8 crore and consolidated profit after tax (PAT) rising 30% to ₹173.6 crore. The company also recommended a final dividend of ₹1.35 per share.

Advanced Enzyme Technologies FY26: Record Revenue & Robust Profit Growth

₹745.8 crore Consolidated Revenue for FY 2025-26
₹173.6 crore Consolidated PAT for FY 2025-26

Reader Takeaway: Record revenue and strong PAT growth driven by operational efficiency and diversification, despite geopolitical and cost concerns.

What just happened

Advanced Enzyme Technologies Ltd announced its financial results for the fiscal year ended March 31, 2026. The company reported a consolidated revenue of ₹745.8 crore, marking a 17.1% increase from ₹636.9 crore in the previous fiscal year (FY 2024-25). Consolidated Profit After Tax (PAT) saw a significant surge of 29.6%, reaching ₹173.6 crore compared to ₹134.0 crore in FY 2024-25. EBITDA also grew by 17.8% to ₹229.1 crore.

Why this matters

These results underscore a period of strong growth and profitability for Advanced Enzyme Technologies. The substantial increase in revenue and PAT, coupled with steady EBITDA margins, indicates effective business strategies and operational execution. The company's performance is a positive signal for shareholders, reflecting its ability to expand its market presence and manage its finances effectively.

The backstory

For FY 2025-26, Advanced Enzyme Technologies achieved its highest-ever annual consolidated revenue. This performance builds on previous years' efforts in product innovation and market expansion. The company has been strategically investing in research and development and diversifying its business segments, including a growing presence in the consumer space with its 'WELLFA' brand.

What changes now

The company's Board has recommended a final dividend of ₹1.35 per share for FY 2025-26, adding to the interim dividend of ₹4 per share already paid. This brings the total dividend payout for the fiscal year to ₹5.35 per share, rewarding shareholders for the company's strong financial performance.

Risks to watch

Investors should remain aware of potential risks, including geopolitical uncertainties in West Asia and disruptions in regional trade, which could impact supply chains. Additionally, rising input costs for essential materials like energy, packaging, and solvents could put pressure on manufacturing margins going forward.

Peer comparison

While specific peer data is not provided in the filing, Advanced Enzyme Technologies' reported growth rates of over 17% in revenue and nearly 30% in PAT suggest a competitive performance within the enzyme manufacturing sector. The company's focus on R&D and B2C diversification also positions it uniquely.

Context metrics (time-bound)

• FY 2025-26 Consolidated Revenue: ₹745.8 crore (+17.1% YoY)
• FY 2025-26 Consolidated PAT: ₹173.6 crore (+29.6% YoY)
• FY 2025-26 Consolidated EBITDA: ₹229.1 crore (+17.8% YoY)
• Total Dividend for FY 2025-26: ₹5.35 per share
• R&D Investment in FY 2025-26: ₹24.6 crore

What to track next

Investors will be keen to observe how Advanced Enzyme Technologies continues to manage input cost pressures and geopolitical risks. Monitoring the growth trajectory of its consumer segment and the success of its ongoing R&D initiatives will be crucial for future value creation.